WALDENSTROM MACROGLOBULINEMIA
Clinical trials for WALDENSTROM MACROGLOBULINEMIA explained in plain language.
Never miss a new study
Get alerted when new WALDENSTROM MACROGLOBULINEMIA trials appear
Sign up with your email to follow new studies for WALDENSTROM MACROGLOBULINEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets rare blood cancer in early trial
Disease control Not yet recruitingThis study tests a combination of three drugs (nemtabrutinib, bortezomib, and rituximab) in people with Waldenstrom's macroglobulinemia, a rare blood cancer. The goal is to see how well the treatment shrinks tumors and controls the disease. About 19 adults who have not been treat…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New drug targets Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-stage study tests a new drug called LY4152199 in people with B-cell cancers like lymphoma that have not responded to prior treatments. The main goals are to find the safest dose and see if the drug can shrink tumors. About 215 adults will take part, and those who benef…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
New combo therapy targets Hard-to-Treat blood cancer
Disease control Not yet recruitingThis study tests the safety and effectiveness of combining two drugs, mosunetuzumab and pirtobrutinib, in 25 adults with Waldenstrom macroglobulinemia that has returned or not responded to prior treatment. Participants must have had at least one prior therapy, including a BTK inh…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: University of Utah • Aim: Disease control
Last updated May 18, 2026 12:14 UTC
-
New pill combo shows promise for rare blood cancer
Disease control Not yet recruitingThis study tests a combination of two oral medications, zanubrutinib and BGB-11417, in people with Waldenström macroglobulinemia who have already received at least one prior treatment. The goal is to see if the combo can shrink or control the cancer better than current options. A…
Matched conditions: WALDENSTROM MACROGLOBULINEMIA
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated May 15, 2026 11:54 UTC